Studies show that use of pulsed electromagnetic field (PEMF) treatment after anterior cervical discectomy and fusion (ACDF) significantly increased the fusion rate vs. control at 6 and 12 months, for participants at risk for pseudoarthrosis.
The evaluations used historical data from Orthofix’s 2014 investigational device exemption premarket approval study of 323 patients conducted plus data from a new multicenter, retrospective cohort study of 274 patients. In the latter, participants were required to have one or more risk factors for pseudoarthrosis (failure to fuse). All were treated with PEMF following ACDF.
Cervical-Stim is FDA-approved for use as an adjunct to cervical spinal fusion and is the only bone growth therapy device approved by FDA as a noninvasive, adjunctive treatment option for cervical fusion in high risk patients.
Source: Orthofix International N.V.
Studies show that use of pulsed electromagnetic field (PEMF) treatment after anterior cervical discectomy and fusion (ACDF) significantly increased the fusion rate vs. control at 6 and 12 months, for participants at risk for pseudoarthrosis.
The evaluations used historical data from Orthofix’s 2014 investigational device exemption premarket...
Studies show that use of pulsed electromagnetic field (PEMF) treatment after anterior cervical discectomy and fusion (ACDF) significantly increased the fusion rate vs. control at 6 and 12 months, for participants at risk for pseudoarthrosis.
The evaluations used historical data from Orthofix’s 2014 investigational device exemption premarket approval study of 323 patients conducted plus data from a new multicenter, retrospective cohort study of 274 patients. In the latter, participants were required to have one or more risk factors for pseudoarthrosis (failure to fuse). All were treated with PEMF following ACDF.
Cervical-Stim is FDA-approved for use as an adjunct to cervical spinal fusion and is the only bone growth therapy device approved by FDA as a noninvasive, adjunctive treatment option for cervical fusion in high risk patients.
Source: Orthofix International N.V.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.